Get the Stockscreener App
52.41
2.87%
1.46
After Hours:
56.15
3.74
+7.14%
Overview
News
Price History
Option Chain
Why NVO Down?
Discussions
Forecast
Stock Split
Dividend History
Novo Nordisk Adr stock is traded at $52.41, with a volume of 15.77M.
It is up +2.87% in the last 24 hours and down -22.03% over the past month.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$50.95
Open:
$51.435
24h Volume:
15.77M
Relative Volume:
1.12
Market Cap:
$177.68B
Revenue:
$45.44B
Net Income/Loss:
$16.18B
P/E Ratio:
14.42
EPS:
3.634
Net Cash Flow:
$9.21B
1W Performance:
+2.60%
1M Performance:
-22.03%
6M Performance:
-32.70%
1Y Performance:
-61.90%
1-Day Range:
$51.37
$52.75
1-Week Range:
$49.38
$52.75
52-Week Range:
$45.05
$139.74
Novo Nordisk Adr Stock (NVO) Company Profile
Name
Novo Nordisk Adr
Sector
Industry
Phone
-
Address
-
Compare NVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
52.41 | 226.39B | 45.44B | 16.18B | 9.21B | 3.634 |
|
LLY
Lilly Eli Co
|
701.23 | 613.56B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
176.64 | 420.78B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
206.69 | 361.58B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
124.21 | 236.35B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.21 | 206.72B | 63.43B | 16.42B | 14.72B | 6.49 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Aug-05-25 | Downgrade | UBS | Buy → Neutral |
| Jul-31-25 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-30-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-17-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Mar-13-25 | Upgrade | Kepler | Hold → Buy |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-06-25 | Upgrade | Bernstein | Underperform → Mkt Perform |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-12-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Neutral |
| Dec-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-02-23 | Initiated | Argus | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-15-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-28-22 | Downgrade | UBS | Neutral → Sell |
| Jun-27-22 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Jun-07-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-31-22 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-22 | Upgrade | Cowen | Market Perform → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-16-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-25-22 | Downgrade | Liberum | Hold → Sell |
| Dec-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-17-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-20-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jul-06-20 | Downgrade | BofA Securities | Buy → Neutral |
| May-11-20 | Downgrade | UBS | Buy → Neutral |
| May-04-20 | Initiated | Cowen | Market Perform |
| Mar-16-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-20 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-18-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-17-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-30-19 | Downgrade | Jefferies | Hold → Underperform |
| Jun-20-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-11-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Apr-29-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-29-19 | Initiated | Exane BNP Paribas | Outperform |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Dec-29-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-06-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-01-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-25-17 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Sep-06-17 | Upgrade | BofA/Merrill | Underperform → Neutral |
View All
Novo Nordisk Adr Stock (NVO) Latest News
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming DeadlinesNVO - Finansavisen
Is Novo Nordisk A s (b Shares) Adrhedged stock ready for a breakoutTreasury Yields & Community Verified Swing Trade Signals - Newser
Using Ichimoku Cloud for Novo Nordisk A s (b Shares) Adrhedged technicalsQuarterly Market Summary & Verified Momentum Watchlists - Newser
What’s next for Novo Nordisk A s (b Shares) Adrhedged stock priceRecession Risk & Community Consensus Picks - Newser
Is Novo Nordisk A s (b Shares) Adrhedged showing signs of accumulationTreasury Yields & Weekly Hot Stock Watchlists - Newser
Predicting Novo Nordisk A s (b Shares) Adrhedged trend using moving averagesWeekly Investment Report & AI Enhanced Trade Execution Alerts - Newser
Full technical analysis of Novo Nordisk A s (b Shares) Adrhedged stockJuly 2025 Update & High Accuracy Trade Alerts - Newser
New Product Launches: Will They Boost Novo Nordisk A s (b Shares) Adrhedged Stock in 20252025 Geopolitical Influence & AI Enhanced Trading Signals - Newser
Novo Nordisk A s (b Shares) Adrhedged’s volatility index tracking explained2025 Retail Activity & Risk Managed Investment Signals - Newser
How to monitor Novo Nordisk A s (b Shares) Adrhedged with trend dashboardsPortfolio Value Report & Expert Verified Stock Movement Alerts - Newser
Earnings visualization tools for Novo Nordisk A s (b Shares) AdrhedgedEarnings Summary Report & Community Driven Trade Alerts - Newser
European ADRs Gained Ground In The US Trading Session - Finimize
HIMS & HERS HEALTH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines – NVO - FinancialContent
HIMS & HERS HEALTH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - GlobeNewswire Inc.
European ADRs Slipped As Top Movers Took Center Stage - Finimize
Real time scanner hits for Novo Nordisk A s (b Shares) Adrhedged explainedBuy/Sell Zone Confirmation Technical Analysis - Newser
Novo Nordisk A/S Common Stock (NYSE:NVO) Stock Quote - FinancialContent
Will a bounce in Novo Nordisk A s (b Shares) Adrhedged offer an exitNext Day Momentum Stock Forecasting Report - Newser
European ADRs Tick Up As Healthcare And Industrials Shine - Finimize
Applying sector rotation models to Novo Nordisk A s (b Shares) AdrhedgedPredictive AI Signals for Short-Term Trading - Newser
Should You Sell Eli Lilly and Buy Novo Nordisk Stock After Q2? - Money Morning
Why Novo Nordisk A s (b Shares) Adrhedged stock attracts strong analyst attentionIntraday Strategy with Real Time Monitoring - Newser
Does Novo Nordisk A s (b Shares) Adrhedged qualify in momentum factor screeningFree Market Surge Signal for Swing Traders - Newser
Published on: 2025-08-06 19:02:41 - Newser
Novo Nordisk Earnings: CVS Deal, Oral Semaglutide Support Growth Despite Compounding Uncertainty - Morningstar
Is Novo Nordisk A s (b Shares) Adrhedged trending in predictive chart modelsFree AI Screening for Swing Trade Picks - Newser
Novo Nordisk lowers 2025 sales outlook, ADR price falls 21.83%. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/SNVO - cnhinews.com
Novo Nordisk ADR earnings beat by $0.04, revenue fell short of estimates - Investing.com
Novo Nordisk A/S Announces 7% Increase in Interim Dividend for 2025, Payment Dates Set - AInvest
Novo Nordisk ADR earnings beat by $11.56, revenue topped estimates - Investing.com India
Novo Nordisk Adr Stock (NVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.13%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):